Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Drug Discovery Programme | 07/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy